The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …

Hepatocellular carcinoma is the third leading cause of deaths from cancer worldwide.
Infection with the hepatitis B virus is one of the leading risk factors for developing …

Simple Summary The mitogen-activated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) signaling pathway is frequently activated in liver cancer, which is one of the …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer, both at the molecular
and histological level. High-throughput sequencing and gene expression profiling have …

Hepatic fibrogenesis is a pathophysiological outcome of chronic liver injury hallmarked by
excessive accumulation of extracellular matrix proteins. Fibrosis is a dynamic process that …

Although hepatocellular carcinoma (HCC) is one of the deadliest health burdens worldwide,
few drugs are available for its clinical treatment. However, in recent years, major …

Primary liver cancer is the second leading cause of cancer-related death worldwide and
therefore a major public health challenge. We review hypotheses of the cell of origin of liver …

Background & aims Agents that induce an immune response against tumors by altering T-
cell regulation have increased survival times of patients with advanced-stage tumors, such …